Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

732 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Notch inhibition overcomes resistance to tyrosine kinase inhibitors in EGFR-driven lung adenocarcinoma.
Bousquet Mur E, Bernardo S, Papon L, Mancini M, Fabbrizio E, Goussard M, Ferrer I, Giry A, Quantin X, Pujol JL, Calvayrac O, Moll HP, Glasson Y, Pirot N, Turtoi A, Cañamero M, Wong KK, Yarden Y, Casanova E, Soria JC, Colinge J, Siebel CW, Mazieres J, Favre G, Paz-Ares L, Maraver A. Bousquet Mur E, et al. Among authors: soria jc. J Clin Invest. 2020 Feb 3;130(2):612-624. doi: 10.1172/JCI126896. J Clin Invest. 2020. PMID: 31671073 Free PMC article.
Long term analysis of survival in the European randomized trial comparing vinorelbine/cisplatin to vindesine/cisplatin and vinorelbine alone in advanced non-small cell lung cancer.
Le Chevalier T, Brisgand D, Soria JC, Douillard JY, Pujol JL, Ruffie P, Aberola V, Cigolari S. Le Chevalier T, et al. Among authors: soria jc. Oncologist. 2001;6 Suppl 1:8-11. doi: 10.1634/theoncologist.6-suppl_1-8. Oncologist. 2001. PMID: 11181998 Free article. Clinical Trial.
Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer.
Soria JC, Márk Z, Zatloukal P, Szima B, Albert I, Juhász E, Pujol JL, Kozielski J, Baker N, Smethurst D, Hei YJ, Ashkenazi A, Stern H, Amler L, Pan Y, Blackhall F. Soria JC, et al. J Clin Oncol. 2011 Nov 20;29(33):4442-51. doi: 10.1200/JCO.2011.37.2623. Epub 2011 Oct 17. J Clin Oncol. 2011. PMID: 22010015 Clinical Trial.
A comparative and integrative approach identifies ATPase family, AAA domain containing 2 as a likely driver of cell proliferation in lung adenocarcinoma.
Fouret R, Laffaire J, Hofman P, Beau-Faller M, Mazieres J, Validire P, Girard P, Camilleri-Bröet S, Vaylet F, Leroy-Ladurie F, Soria JC, Fouret P. Fouret R, et al. Among authors: soria jc. Clin Cancer Res. 2012 Oct 15;18(20):5606-16. doi: 10.1158/1078-0432.CCR-12-0505. Epub 2012 Aug 22. Clin Cancer Res. 2012. PMID: 22914773
Phase I-IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours.
Soria JC, Baselga J, Hanna N, Laurie SA, Bahleda R, Felip E, Calvo E, Armand JP, Shepherd FA, Harbison CT, Berman D, Park JS, Zhang S, Vakkalagadda B, Kurland JF, Pathak AK, Herbst RS. Soria JC, et al. Eur J Cancer. 2013 May;49(8):1815-24. doi: 10.1016/j.ejca.2013.02.012. Epub 2013 Mar 13. Eur J Cancer. 2013. PMID: 23490650 Clinical Trial.
Open-label, multicentre expansion cohort to evaluate imgatuzumab in pre-treated patients with KRAS-mutant advanced colorectal carcinoma.
Delord JP, Tabernero J, García-Carbonero R, Cervantes A, Gomez-Roca C, Bergé Y, Capdevila J, Paz-Ares L, Roda D, Delmar P, Oppenheim D, Brossard SS, Farzaneh F, Manenti L, Passioukov A, Ott MG, Soria JC. Delord JP, et al. Among authors: soria jc. Eur J Cancer. 2014 Feb;50(3):496-505. doi: 10.1016/j.ejca.2013.10.015. Epub 2013 Nov 18. Eur J Cancer. 2014. PMID: 24262587 Clinical Trial.
732 results